Episode Details

Do you know that personalized solutions are more precise and targeted and offer direct mediation? Do you need insights about dealing with cancer? Join Dr. Jeffrey Gladden, Steve Reiter and John Catanzaro in this episode of the Gladden Longevity Podcast. John Catanzaro is the CEO, Founder, and Product Development Officer of Neo7Bioscience, a precision/personalized molecular design biotech company. He retired from clinical practice in 2017, where he was the Founder and CEO of a cancer institute and research development of genetic and proteomic technology innovating patient-precision genetically matched immunopeptides. He is the co-inventor of a precision augmentation platform known as PBIMA. The platform includes multiomic / proteomic sequencing and prediction, CRISPR prime editing features, and proteomics in a 3D integration utilizing unified proprietary mapping informatics and computation, superior ranking, and selection architecture. In this episode, they talk about the hidden root cause that creates disharmony in the body, the importance of a complete molecular assessment, and why individualized therapeutic solutions using peptides are the way to go. Do you know that individualized health is the root of resilience and longevity? Are you interested in decoding and measuring again? Listen to find out more.

Listen to this episode to learn about making 100 the new 30, and living beyond 120!

Dr. Gladden comments that this is one of the most forward-looking podcasts they have ever done. (1:04)

Dr. Gladden shares how excited he is for John to join him and welcomes him to the show. (3:00)

John explains how they isolate a patient's protein. (5:02)

John speaks about how protein signals are captured by doing in-depth analysis. (7:02)

John clarifies how deep learning, AI, and machine learning are used to make sense of large amounts of data. (9:15)

John breaks down how they are turning the complexities found in disease pathways into viable solutions. (12:30)

Listen Now